Browse News
Filter News
Found 8,245 articles
-
Pelthos Therapeutics Establishes Board of Directors
4/16/2024
Pelthos Therapeutics today announced it has appointed five seasoned industry professionals to serve on its Board of Directors.
-
Cardiawave appoints Olivier Pierron as its Chief Executive Officer
4/16/2024
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as its new Chief Executive Officer.
-
Hyalex Orthopaedics Appoints Thomas Vail, M.D., as Chief Medical Officer and Names Adam Gridley to Board of Directors
4/15/2024
Hyalex Orthopaedics, a privately held medical device company developing cartilage repair products based on the transformative HYALEX® materials platform, announced the appointment of Thomas "Tad" Vail, M.D., as chief medical officer.
-
STALICLA Appoints Dr. Thomas Blaettler, MD
4/11/2024
STALICLA SA announced the appointment of Thomas Blaettler, to the position of Chief Medical Officer.
-
7 Billion-Dollar Oncology M&As from Q1
4/10/2024
AbbVie’s $10.1 billion takeover of ImmunoGen paces the cancer sector in early 2024, as ADCs and radiopharmaceuticals remain hot. -
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
4/10/2024
Terns Pharmaceuticals, Inc. announced the appointment of Melita Sun Jung as chief business officer, effective April 22, 2024.
-
NeurAxis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
4/9/2024
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2023 for the period ended December 31, 2023.
-
Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer
4/8/2024
Gain Therapeutics, Inc. announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024.
-
Contineum Therapeutics priced its initial public offering Friday, scaling back its expectations for gross proceeds of $110 million for clinical trials of a challenger to Boehringer Ingelheim and Roche.
-
OrganOx Announces Appointment of Stephen M. Deitsch as new Chief Financial Officer
4/4/2024
OrganOx today announces that Stephen (Steve) M. Deitsch will be joining OrganOx as Chief Financial Officer (“CFO”) on April 8, 2024.
-
Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer
4/3/2024
Q32 Bio Inc., a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, announced the appointment of Lee Kalowski as President and Chief Financial Officer.
-
Fresh from its IPO, Fractyl Health got an Investigational Device Exemption from the FDA, clearing a pivotal study of its Revita system to help maintain weight loss following the discontinuation of GLP-1 drugs.
-
Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement
4/1/2024
Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc., announced a clinical collaboration agreement to further accelerate the clinical research program of Teva’s ICS-SABA.
-
NeurAxis to Host Fourth Quarter and Full Year 2023 Results and Business Update Call on Tuesday, April 9, 2024
4/1/2024
NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, will report financial results for its fourth quarter and fiscal year 2023, for the period ended December 31, 2023, on Tuesday, April 9, 2024, after the close of the market.
-
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/1/2024
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company focused on pioneering new approaches for the treatment of type 2 diabetes (T2D) and obesity, today reported its fourth quarter and full year 2023 financial results and provided a business update.
-
Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/1/2024
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported fourth quarter and full year 2023 financial results and business updates.
-
AEON Biopharma Announces Redemption of Public Warrants - March 29, 2024
3/29/2024
AEON Biopharma, Inc. announced that the Company will redeem all of its outstanding warrants to purchase shares of the Company’s Class A common stock, par value $0.0001 per share, that were issued under the Warrant Agreement, dated February 8, 2021, by and between the Company and Continental Stock Transfer & Trust Company.
-
Continuing 2024’s biotech initial public offering rally, Boundless Bio will debut Thursday on the Nasdaq with the proceeds used to advance its pipeline of extrachromosomal DNA cancer assets.
-
Cell And Gene Therapy CDMO Market Size to Reach USD 69.11 Bn by 2033
3/28/2024
The global cell and gene therapy CDMO Market size was valued at USD 5.90 billion in 2023 and is projected to reach USD 69.11 billion by 2033,
-
ArriVent BioPharma Reports Full Year 2023 Financial Results
3/28/2024
ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended December 31, 2023, and highlighted recent company progress.